Our consumer-facing, educational community that helps people of color take control of their health and encourages participation in clinical trials both digitally and in person.
ANALYSIS & INSIGHT
Predictive analytics technology that tracks interest and reports on community engagement at the individual level to help organizations better plan for, execute, and learn from diversity in clinical trials.
Start with insight drawn from our engaged community and plan your next trial with equity in mind from the start. Acclinate can help your organization get ahead in its diversity efforts.
Get a clear view of the health of your current initiatives and create a plan for improvement by implementing our Affective Trust Framework in your clinical trials.
Increase equity acumen throughout your organization with custom training programs designed to help staff overcome challenges engaging communities of color in trial participation.
Acclinate’s increase in total pre-screened patients, accomplished in a third of the time.
Of those who passed the prescreener answered a call from Acclinate expressing interest in participating.
Sometimes, people do not know how to gain access to clinical trials. Our partnership with Acclinate leverage[d] their established, trusted community connections, digital platform, and app with Lightship’s robust clinical trial infrastructure and commitment to meeting participants where they are to deliver their clinical trial.
No. We’re a catalyst that turns community trust, data analysis, and insight into products that help healthcare organizations increase equity in their trials and initiatives. We do not recruit participants. Rather, we cultivate educated, empowered communities around specific health conditions and engage with them to encourage clinical trial participation. Our metrics end with pre-screened, pre-qualified candidates. Your organization then selects who to recruit.
We have three levels of pricing, based on engagement scope.
Study Level Pricing - This pricing is based on one study and is centered in a defined set of metro areas within which Acclinate will engage potential participants. Duration is defined by a timeline that begins with the first patient enrolled (FPI) and ends with the last patient enrolled (LPI) in the study. Additional metro areas can be included for an added fee.
Program Level Pricing - This pricing is based on a set of highly related studies aligned to a specific therapeutic area in which all use the same set of metro areas. Duration is defined by a timeline that begins with the first patient enrolled (FPI) in the earliest study and ends with the last patient enrolled (LPI) in the final study.
Enterprise Level Pricing - This pricing is based on sustained engagement of a defined set of metro areas around a specific therapeutic area (TA) or set of TAs. Separate scope of work agreements are created for each study associated with the TA.
The earlier, the better. Our model includes three distinct stages: (1) early engagement; (2) awareness; and (3) participation. Ideally, we will require at least 3 months before the start of trial enrollment to conduct our early engagement and awareness that builds trust and gathers necessary data for our platform. Some sponsors opt to engage with us even earlier, at an indication, therapeutic area, or program level, and engage us in disease and clinical research education to prepare a pool of potentially interested participants for an upcoming trial.
If a trial has already begun enrolling, we can still conduct our work, but we would still require three months of lead time before significant potential participants can be identified and presented with the trial. As such, the longer you wait, the less value we can offer. However, our experience is that the issue of diversity is taken more seriously once an organization can quantifiably see that they are not getting adequate representation in their current trials (enough to meet FDA expectations), so no matter what, it is often a great time to discuss using Acclinate for upcoming trials.
Sponsors running trials for indications or therapeutic areas that disproportionately impact communities of color will find the greatest value from working with us. For example, Black Americans are twice as likely as older White Americans to suffer from Alzheimer's or another dementia. Therefore, running an Alzheimer’s trial without adequate Black representation could pose a problem for a sponsor. Specific focus areas include (but are not limited to) cancer, diabetes, sick cell, cardiovascular, kidney disease, neurological, and autoimmune disorders. In certain instances, we will also engage sponsors in rare disease trials.
We are presently hyper-focused on Black/African American communities, which make up the largest percentage of our community members. However, we do serve other racial and ethnic communities as well and are currently expanding our focus communities to include Indigenous American communities, with LatinX and Hispanic communities as a fast follow.
Once we gain an understanding of the sponsor, indication, and high-level details of the trial, our team will conduct a preliminary assessment with an "accept or reject'' decision from our Chief Medical Lead within two business days. If we "accept” the work, we then request the following:
Our team will then conduct a detailed population and site data analysis to determine access potential and craft a detailed approach and proposal developed within five business days of receiving the above information.